Decision Making in Lung Cancer – How Applicable are the Guidelines?

Vinod, Shalini

doi:10.1016/j.clon.2014.10.008

Cited by 19 publications

(11 citation statements)

References 28 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neither was age associated with survival. This reinforces the fact that patients should not be precluded from curative treatment based on age alone …”

Section: Discussionsupporting

confidence: 60%

Radiotherapy patterns of care for stage I and II non‐small cell lung cancer in Sydney, Australia

Nguyen

Wong²,

Beydoun

et al. 2018

J Med Imag Rad Onc

View full text Add to dashboard Cite

Introduction: Curative radiotherapy is guideline treatment for inoperable patients of good performance status with Stage I & II Non-Small Cell Lung Cancer (NSCLC). The aim of this study was to evaluate radiotherapy patterns of care in these patients, the reasons for palliative treatment and the proportion of patients suitable for curative stereotactic ablative body radiotherapy (SABR). Methods: Electronic oncology databases at three institutions were queried to retrieve data on patients with inoperable Stage I & II NSCLC seen in radiation oncology clinics between 1/1/2008 and 31/12/2014. Suitability for SABR was defined as peripheral tumours less than 5 cm in size. Factors associated with curative treatment were determined using univariate and multivariate analyses. Results: Three-hundred-and-twelve patients were identified of whom 178 (57%) received curative radiotherapy, 58 (19%) palliative radiotherapy and 76 (24%) no radiotherapy. The main reason for receiving palliative rather than curative treatment was COPD or poor pulmonary function (26%). Method of diagnosis (P = 0.031), Simplified Comorbidity Score (P = 0.003), ECOG performance status (P = 0.016), FEV1% (P = 0.040), treating institution (P < 0.0001) and time period (P = 0.016) were associated with curative radiotherapy on multivariate analysis. In patients with T1-2N0M0 NSCLC, 19 (31%) who did not receive treatment and 7 (21%) who underwent palliative radiotherapy were technically and clinically suitable for SABR. Conclusion: Only 57% of patients with Stage I-II NSCLC were treated with curative radiotherapy. Patient factors were the predominant reason for palliative treatment, however, treating institution also played a role. A considerable proportion of patients who underwent palliative or no radiotherapy were suitable for SABR treatment.

show abstract

“…Neither was age associated with survival. This reinforces the fact that patients should not be precluded from curative treatment based on age alone …”

Section: Discussionsupporting

confidence: 60%

Radiotherapy patterns of care for stage I and II non‐small cell lung cancer in Sydney, Australia

Nguyen

Wong²,

Beydoun

et al. 2018

J Med Imag Rad Onc

View full text Add to dashboard Cite

show abstract

“…Decision-making in lung cancer is a complex process requiring integration of multimodality treatment, with guideline adherence for patients with in lung cancer ranging from 44% to 52%. 61 Moreover, some patients refuse invasive biopsy procedures or surgical treatment while they are regarded medically operable based on pulmonary function.…”

Section: Strengths and Limitationsmentioning

confidence: 99%

Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis

Ijsseldijk

Shoni

Siegert

et al. 2019

Journal of Thoracic Oncology

View full text Add to dashboard Cite

Introduction: Stereotactic body radiation therapy (SBRT) is a promising curative treatment for early-stage NSCLC. It is unclear if survival outcomes for SBRT are influenced by a lack of pathological confirmation of malignancy and staging of disease in these patients. In this systematic review and meta-analysis, we assess survival outcomes after SBRT in studies with patients with clinically diagnosed versus biopsy-proven early-stage NSCLC.

show abstract

“…Internationally, numerous clinical practice guidelines (CPGs) have been developed in order to provide a framework for evidence-based best practice care to guide clinician decisionmaking. 1 How CPGs and other standard of care are implemented into daily practice needs to be measured to be able to identify areas for quality improvement and address barriers to care, to ensure the delivery of high-quality care.…”

Section: Introductionmentioning

confidence: 99%

Quality indicators in lung cancer: a review and analysis

et al. 2021

View full text Add to dashboard Cite

Contributed to conception of design, analysis and interpretation of data, final approval. SKV: Contributed to conception of design, analysis and interpretation of data, critical revision of work, final approval. PS: Contributed to conception of design, critical revision of work, final approval. BJ: Contributed to conception of design, critical revision of work and final approval. SC: Contributed to conception of design, critical revision of work and final approval.

show abstract

Decision Making in Lung Cancer – How Applicable are the Guidelines?

Cited by 19 publications

References 28 publications

Radiotherapy patterns of care for stage I and II non‐small cell lung cancer in Sydney, Australia

Radiotherapy patterns of care for stage I and II non‐small cell lung cancer in Sydney, Australia

Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis

Quality indicators in lung cancer: a review and analysis

Contact Info

Product

Resources

About